Karine Tawagi

Hematology

5333 McAuley Dr Rm 4001
Ypsilanti, MI 48197

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Artificial Intelligence Among US Hematology Oncology Fellows: A Multicenter Survey of Education, Attitudes, and Clinical Use.

Artificial Intelligence Among US Hematology Oncology Fellows: A Multicenter Survey of Education, Attitudes, and Clinical Use.

Journal: JCO oncology practice

Published: May 31, 2026

Correction: Navigating drug-drug interactions with apalutamide.

Correction: Navigating drug-drug interactions with apalutamide.

Journal: Prostate cancer and prostatic diseases

Published: March 20, 2026

State-Level Prevalence of Obesity/overweight and Pancreatic Cancer Incidence in the United States: An Ecological Analysis Using BRFSS, CDC WONDER and ACS for the Year 2021.

State-Level Prevalence of Obesity/overweight and Pancreatic Cancer Incidence in the United States: An Ecological Analysis Using BRFSS, CDC WONDER and ACS for the Year 2021.

Journal: Journal of gastrointestinal cancer

Published: February 21, 2026

The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.

The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.

Journal: Cancer

Published: December 22, 2025

Assessment of Fellowship Didactic Curricula in Hematology/Oncology: Cross-Sectional Findings From the PODCAST-HOF Trial.

Assessment of Fellowship Didactic Curricula in Hematology/Oncology: Cross-Sectional Findings From the PODCAST-HOF Trial.

Journal: Journal of cancer education : the official journal of the American Association for Cancer Education

Published: October 31, 2025

Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.

Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.

Journal: Cancer

Published: October 01, 2025

Peri-operative management considerations for localised upper tract urothelial carcinoma in the setting of Lynch syndrome.

Peri-operative management considerations for localised upper tract urothelial carcinoma in the setting of Lynch syndrome.

Journal: BMJ case reports

Published: October 01, 2025

Navigating drug-drug interactions with apalutamide.

Navigating drug-drug interactions with apalutamide.

Journal: Prostate cancer and prostatic diseases

Published: October 01, 2025

Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists.

Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists.

Journal: Clinical genitourinary cancer

Published: July 16, 2025

Educational Impact of a Podcast Curriculum for Hematology/Oncology Fellows: Final Results of the Multicenter Cluster Randomized PODCAST-HOF Trial.

Educational Impact of a Podcast Curriculum for Hematology/Oncology Fellows: Final Results of the Multicenter Cluster Randomized PODCAST-HOF Trial.

Journal: JCO oncology practice

Published: May 31, 2025

Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers.

Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers.

Journal: Breast cancer research and treatment

Published: May 13, 2025

Next-generation sequencing identifies the presence of protein phosphatase 1D, PPM1D, as a potential biomarker of resistance to PARP inhibition in metastatic castration-resistant prostate cancer.

Next-generation sequencing identifies the presence of protein phosphatase 1D, PPM1D, as a potential biomarker of resistance to PARP inhibition in metastatic castration-resistant prostate cancer.

Journal: American journal of clinical and experimental urology

Published: October 30, 2024

Showing 1-12 of 23

Last Updated: 09/26/2026